HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection
Conditions
Keywords
HBe, Hepatitis, Vireda (TENOFOVIR, CLEVUDINE), HBV, HBe Ag negative
Brief summary
For chronic HBV infection, an optimal pharmacological agent to promote recovery from chronic HBV infection would be one that inhibits HBV DNA polymerase, combined with the clearence from the liver of cccDNA to block HBV reactivation after the circulating viral burden has been eliminated by therapy. The activity of clevudine on cccDNA in combination with its potent antiviral activity on HBV polymerase makes it the optimal agent in combination with tenofovir for this protocol.
Interventions
DRUGCLEVUDINE + TENOFOVIR PLACEBO
30 MG
DRUGCLEVUDINE IN ASSOCIATION TENOFOVIR
TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
DRUGTENOFOVIR + CLEVUDINE PLACEBO
TENOFOVIR 300 mg qd + CLEVUDINE Placebo
Sponsors
French National Agency for Research on AIDS and Viral Hepatitis
Gilead Sciences
Pharmasset
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients over 18 years of age * Chronic hepatitis B, HBs Ag-positive for over 6 months, anti HBs negative * Patients with HBeAg- negative chronic hepatitis B (CHB) and anti-HBe positive at screen * Patients naïve to anti-HBV nucleoside or nucleotide and any other experimental nucleoside/nucleotide analog for HBV * Serum HBV-DNA quantifiable over 2000 IU/mL at screening * ALT over 1.25 ULN and below 10 ULN * Liver biopsy (baseline or within prior 6 months) with evidence of chronic hepatic inflammatory injury (Metavir Activity score over 1 ; Knodell necroinflammatory score over 3, Ishak score over 1)
Exclusion criteria
* Cirrhosis or bridging fibrosis on liver biopsy * Subjects who have received any form of alpha interferon in the past 6 months prior to the first administration of randomized treatment * Any systemic anti-viral, anti-neoplastic or immuno-modulatory treatment (including supraphysiologic doses of steroids and radiation) below 6 months prior to the first dose of randomized treatment and during the study (except for below 10 days of acyclovir for herpetic lesions, or prednisone below 10 mg/days for below 10 days more than 1 month) * Women with ongoing pregnancy or breast feeding * Positive test at screening for anti-HAV IgM Ab, anti-HIV Ab, anti-HCV Ab, HCV RNA, anti-HDV Ab * History or other evidence of a medical condition associated with chronic liver disease other than HBV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease including Wilson's disease and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, toxic thalassemia, NASH) * History or other evidence of bleeding from esophageal varices or other clinical conditions consistent with decompensated liver disease (defined by one of the following criteria being met: serum albumin below 3.5 g/L, prothrombin time over 4 seconds prolonged, serum bilirubin over 34 µmol/L, history of encephalopathy, history of ascites) * Neutrophil count below 1200 cells/mm3 or platelet count below 90,000 cells/mm3 at screening * Serum creatinine level over 130µmol/l or calculated creatinine clearance below 70 ml/min (Cockcroft-Gault) * Evidence or history of tubular nephropathy , Fanconi syndrom or hypophosphoremia. * Evidence of drug abuse (including excessive alcohol consumption) within one year of study entry * History of a severe seizure disorder or current anticonvulsant use * History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis etc.) * History of major organ transplantation with an existing functional graft * History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study * Evidence of an active or suspected cancer or a history of malignancy where the risk of recurrence is over 20 % within 2 years * Patients with a value of alpha-fetoprotein over 100 ng/mL are excluded, unless stability (less than 10 % increase) has been documented over at least the previous 3 months * Patients included in another trial within 8 weeks prior to screening * Inability or unwillingness to provide informed consent or abide by the requirements of the study Reassessments : If a patient fails to meet the above inclusion /
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare the long term efficacy of new anti-HBV strategies of CLV monotherapy VS TDF monotherapy VS the combination of CLV + TDF for 96 weeks in HBeAg negative patients with CHB, naïve to anti-HBV-therapy, at 24 weeks post-treatment | At 120 week |
Secondary
| Measure | Time frame |
|---|---|
| Compare the safety profile of CLV + TDF compared to that of CLV and TDF in HBeAg negative patients with CHB, naïve to anti-HBV-therapy. - To compare perceived toxicity as expressed by the nature and the number of self-reported side effects, percept | At 24 week, 48 week and 96 week |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORMARC BOURLIERE, MD
Hôpital Saint Joseph, marseille, France
Outcome results
None listed